The Department of Health and Social Care updated its response on the statutory scheme for branded health service medicines on 10 June 2026. For pharmaceutical companies, wholesalers and market-access teams, the details matter because pricing policy shapes the commercial environment in which NHS medicines are launched, supplied and reviewed.
The statutory scheme sits alongside the voluntary scheme for branded medicines pricing, access and growth, known as VPAG. Both schemes are intended to control the costs of branded medicines to the NHS while supporting access to important medicines on reasonable terms.
What DHSC decided for 2026
DHSC's consultation response says the statutory scheme headline payment percentage for 2026 and beyond will decrease to 16.5%. Because the change comes into effect part way through the year, companies that made statutory scheme payments in the first half of 2026 at the higher 24.3% rate will pay a reduced 8.7% rate from 1 July to 31 December 2026.
The stated aim is to maintain broad commercial equivalence with VPAG. DHSC also decided to use an alternative future adjustment approach through direct engagement with industry and patient group representatives, rather than relying only on repeated full public consultations.
Why pricing policy affects supply planning
Payment percentages are not simply a finance issue. They can influence launch timing, commercial assumptions, contract discussions, demand forecasting, procurement conversations and the appetite for UK market participation.
For supply-chain teams, the lesson is to keep policy changes connected to operational planning. When the commercial framework changes, organisations may need to revisit product forecasts, expected launch timing, wholesale margins, customer communications and the assumptions used when planning stock.
Practical questions for suppliers
Teams involved in branded medicines should ask:
- Does the product sit under the voluntary scheme or statutory scheme?
- Do 2026 payment changes affect expected net pricing or launch economics?
- Are purchasing assumptions still current after the July 2026 change?
- Do pharmacy or clinic customers need clearer communication about availability, not unsupported price promises?
- Are records, batch traceability and product documentation ready for any revised launch plan?
None of this removes the need for product-specific commercial, legal and regulatory review. It does, however, make the case for joining pricing awareness with wholesale operations.
Logan's editorial view
For Logan Pharmaceuticals, the useful position is cautious and practical: monitor the policy environment, keep documentation current, and avoid treating pricing announcements as automatic changes in availability. Pharmaceutical partners can use the product range page and contact page to start a discussion about sourcing requirements and supporting documentation.
Sources
Primary source: DHSC: Response to consultation on changes to the statutory scheme for branded health service medicines, accessed 30 July 2026.